國家衛生研究院 NHRI:Item 3990099045/4726
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 956474      線上人數 : 850
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4726


    題名: A phase II trial of UFUR plus gemcitabine in non-small cell lung cancer patients failing previous platinum-based chemotherapy
    作者: Chen, YM;Perng, RP;Tsai, CM;Whang-Peng, J
    貢獻者: National Institute of Cancer Research
    摘要: Background: Both UFUR (Tegafur/Uracil) and gemcitabine (G) are effective agents against chemo-naïve NSCLC. The effectiveness of combination of these two agents in NSCLC patients failing previous chemotherapy is unknown.Our aim was to evaluate the efficacy of oral UFUR plus G in NSCLC patients who failed previous platinum-based chemotherapy. Methods: Treatment consisted of oral UFUR 200 mg/m2/day from days 1 to 14 and G 1000 mg/m2 intravenous infusion on days 1 and 8, of every 3 weeks. Results: Between June and November 2004, 31 patients were enrolled into the study, and 22 patients went off-study during that period. The present treatment was second-line treatment in 54.5%, and third-line or higher in 45.5%. Analyses of these 22 patients showed: mean age: 66.6, median cycles received: 3.5, and objective response rates of 22.7%. Treatment-related toxicities were mild and few. Grade 3 or 4 haematological toxicities included neutropenia in 3 patients and anemia in 3 patients. No neutropenic fever occurred. Non-haematological toxicities were all less than grade 3, except for grade 3 pneumonitis in 1 patient and grade 3 fatigue in 2 patients. Median time to disease progression was 3.8 months. Conclusions: This study demonstrated that UFUR plus gemcitabine salvage chemotherapy in NSCLC patients who have failed previous platinum-based chemotherapy produces a relatively lower toxicity profile, and a better compliance and response rate than conventional salvage chemotherapy, such as docetaxel treatment, and deserves further study. Updated data will be shown at the meeting.
    日期: 2005-06
    關聯: Journal of Clinical Oncology. 2005 Jun;23(16):Abstract number 694S.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/7296
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000230326604412
    顯示於類別:[彭汪嘉康(1996-2007)] 會議論文/會議摘要

    文件中的檔案:

    沒有與此文件相關的檔案.



    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋